Eurobio Scientific: Capital reduction through cancellation of treasury shares
11 Luglio 2023 - 7:30AM
Eurobio Scientific: Capital reduction through cancellation of
treasury shares
Capital reduction through cancellation of
treasury shares
- Cancellation of 400,000 treasury shares, representing
approximately 3.53% of the share capital
Paris, July
11,
2023
–
7:30
am
Eurobio Scientific
(FR0013240934, ALERS, PEA-PME eligible), a leading French group in
in vitro specialty medical diagnostics and life sciences, today
announced that it has cancelled 400,000 of its own shares,
representing 3.53% of the share capital, pursuant to the
authorisation granted by the 10th resolution of the Annual General
Meeting held on June 13, 2023. Due to the financial market
processing times, this cancellation will take effect on July 12,
2023.
The share capital now amounts to €3,501,814.72,
divided into 10,943,171 shares. Following this cancellation,
Eurobio Scientific still directly holds 709,443 of its own shares
(6.48% of the share capital following the capital reduction), in
addition to the shares held under the liquidity contract (23,922
shares as of June 30, 2023).
The 400,000 shares cancelled were allocated to
cover free share plans for Group employees and were reallocated for
cancellation.
The remaining treasury shares may be used in
line with the Group’s stated objectives for the use of treasury
shares :
- covering free
share plans for Group employees,
- share transfer
in connection with company acquisitions, and
- share
cancellation.
While maintaining the possibility of
implementing the first two objectives, this treasury share
cancellation enables the company to continue its share buyback
program.
All cancelled shares had been bought back under
Eurobio Scientific's share buyback programs in accordance with the
authorisations granted by the General Meetings held on June 27,
2019, in its 12th resolution, and June 23, 2020, in its 6th
resolution.
Reports and descriptions of the share buyback
programs are available on the company's website under the heading
"Reports on share buyback programs" on the page
:https://www.eurobio-scientific.com/en/investors/regulated-information.
Next financial meetingH1 revenues: 24 July 2023
(after market closes)
|
About Eurobio ScientificEurobio Scientific is a
key player in the field of specialty in vitro diagnostics. It is
involved from research to manufacturing and commercialization of
diagnostic tests in the fields of transplantation, immunology and
infectious diseases, and sells instruments and products for
research laboratories, including biotechnology and pharmaceutical
companies. Through many partnerships and a strong presence in
hospitals, Eurobio Scientific has established its own distribution
network and a portfolio of proprietary products in the molecular
biology field. The Group has approximately 290 employees and four
production units based in the Paris region, in Germany, in the
Netherlands and in the United States, and several affiliates based
in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium,
Utrecht in The Netherlands and Milan in Italy.Eurobio Scientific's
reference shareholder is the EurobioNext holding company which
brings together its two directors, Jean-Michel Carle and Denis
Fortier, alongside the "Pépites et Territoires" by AXA &
NextStage AM investment program, managed by NextStage AM. For more
information, please visit: www.eurobio-scientific.comThe company is
publicly listed on the Euronext Growth market in ParisEuronext
Growth BPI Innovation, PEA-PME 150 and Next Biotech indices,
Euronext European Rising Tech label.Symbol: ALERS - ISIN Code:
FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP |
|
|
- 230711CP_Eurobio_Scientific_reduc_capital_EN
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Eurobio Scientific (EU:ALERS)
Storico
Da Nov 2023 a Nov 2024
